Nabumetone

Nabumetone tablets relieve signs and symptoms of osteoarthritis and rheumatoid arthritis. Weigh alternatives and individual cardiovascular, gastrointestinal and renal risks. No pediatric or off-label acute-pain regimen is supplied.

Start 1,000 mg orally as one dose, with or without food. Some patients obtain additional relief at 1,500–2,000 mg/day, in a single or twice-daily regimen; over 2,000 mg/day has not been studied. Patients under 50 kg may be less likely to need over 1,000 mg. Individualize to response and use the lowest effective dose.

The warnings do not recommend treatment in advanced renal disease; if unavoidable, monitor closely. The numeric PK-section renal limits are not permission to disregard this warning. No validated pediatric, hepatic percentage, dialysis replacement or universal missed-dose algorithm is provided.

Known nabumetone/ingredient hypersensitivity, prior asthma/urticaria/allergic-type reaction to aspirin or another NSAID, and the CABG-surgery setting are contraindicated.

The selected label warns of potentially fatal MI/stroke and serious GI bleeding, ulceration or perforation, including events without symptoms. CV risk can occur early/increase with duration; older adults have greater GI risk. CABG use is contraindicated.

Common reported effects include diarrhea, dyspepsia and abdominal pain, with nausea, constipation, dizziness, headache, rash/pruritus, tinnitus and edema also reported. Serious reactions include bleeding, renal/hepatic injury, anaphylaxis and severe skin reactions; do not infer clinical safety from older surrogate endoscopy comparisons.

Aspirin and other NSAIDs add adverse effects and concurrent aspirin is generally not recommended. Warfarin/NSAID GI bleeding effects are synergistic; corticosteroids also increase GI risk. Review all OTC pain products and anticoagulants rather than unintentionally duplicate NSAIDs.

Nabumetone may reduce ACE-inhibitor antihypertensive and diuretic natriuretic effects; monitor pressure, kidney status and diuretic response. Lithium levels may rise and methotrexate toxicity may increase; use appropriate monitoring. Aluminum antacid did not materially alter active-metabolite bioavailability in the cited study, which does not establish compatibility with every drug.

Limit necessary use between about twenty and thirty weeks to the lowest dose/shortest duration; consider amniotic-fluid ultrasound if treatment exceeds forty-eight hours and stop if oligohydramnios develops. Avoid about thirty weeks onward because of ductus closure risk. Earlier pregnancy data are inconclusive. Human milk excretion is unknown; animal active-metabolite milk transfer and possible infant harm warrant deciding between discontinuing nursing or medicine according to maternal need.

Pediatric safety/effectiveness are unestablished. Older adults may have higher active-metabolite exposure and are more vulnerable to serious GI, renal and cardiovascular complications; age findings in trials do not negate cautious selection.

Follow the renal table together with advanced-disease avoidance. Active 6MNA is highly protein bound and not dialyzable. Severe hepatic data are limited; both prodrug activation and further metabolism depend on liver function, so no numeric hepatic regimen is invented. Stop/evaluate suspected liver injury.

Nabumetone is converted to 6-methoxy-2-naphthylacetic acid (6MNA), which inhibits prostaglandin synthesis and accounts for anti-inflammatory activity.

Parent drug is not detected in plasma after rapid biotransformation. 6MNA is more than 99% protein bound; its half-life is approximately twenty-four hours and longer with renal impairment/older age. Metabolites are largely eliminated in urine. Food accelerates appearance/increases peak but does not change overall conversion exposure; renal protein binding makes dialysis ineffective for active-metabolite removal.

Monitor BP, edema, kidney function and bleeding symptoms; long-term use warrants periodic CBC/chemistry as clinically directed. Review liver symptoms and drug combinations. Seek immediate care for chest/stroke symptoms, GI bleeding, breathing/facial swelling or serious rash/systemic fever. Review pregnancy plans and avoid unnecessary OTC NSAIDs. Persistent abnormal liver tests or clinical organ/systemic manifestations require stopping/evaluation.

Seek medical/Poison Control assessment. There is no specific antidote; severe effects include bleeding, kidney injury and respiratory/CNS compromise. Legacy label emesis/cathartic instructions and apparently tolerated large doses are not home-treatment advice or safe thresholds. Dialysis is unlikely to help because of high protein binding.

Product

Bryant Ranch nabumetone 500 mg

Route

Oral film-coated tablet

Appearance

White, oval, biconvex; 3670 / plain

Example package

Bottle 30 · NDC 71335-1234-2

The selected supply record lists 500 mg tablets in several bottle sizes. Other strengths/manufacturers have different identification records; no liquid, injection, pediatric or compounded preparation is reviewed.

Store at 20–25°C in a tight, light-resistant container with the required child-resistant closure. Follow actual expiry; no independently verified crushing/tube or compounded beyond-use protocol is supplied.